Acute Kidney Injury Global Market Report 2025

The acute kidney injury market size has grown strongly in recent years. It will grow from $5.37 billion in 2024 to $5.74 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, growing incidence of hospital-acquired infections, increasing awareness about kidney health, and advancements in critical care medicine.

The acute kidney injury market size is expected to see strong growth in the next few years. It will grow to $7.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The projected growth during the forecast period is driven by the increasing incidence of sepsis, rising demand for personalized treatment, expanding government healthcare initiatives, growing healthcare expenditure in emerging markets, and a strong emphasis on personalized medicine and regenerative therapies. Key trends expected during this period include the development of wearable dialysis devices, the integration of artificial intelligence for treatment optimization, advancements in portable renal replacement therapy systems, innovations in continuous renal replacement therapy (CRRT), and the expansion of remote monitoring and telemedicine solutions.

The increasing prevalence of diabetes is expected to drive the expansion of the acute kidney injury (AKI) market. Diabetes encompasses a group of metabolic diseases characterized by elevated blood sugar levels, either due to insufficient insulin production or the body's inability to use insulin effectively. The rising incidence of diabetes is attributed to factors such as increasing obesity rates, poor dietary habits, sedentary lifestyles, aging populations, and improved awareness and diagnostic capabilities. Acute kidney injury induces metabolic and inflammatory changes that can impact insulin resistance and glucose regulation, creating a complex relationship that may affect diabetes management and progression. For example, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it increased by 21%. Additionally, the proportion of individuals achieving target HbA1c levels reached 37.9%, marking the highest figure ever recorded by the National Diabetes Audit (NDA). Consequently, the rising prevalence of diabetes is fueling the growth of the acute kidney injury market.

Leading companies in the acute kidney injury (AKI) market are prioritizing regulatory approvals to expand their product offerings and introduce novel treatment solutions. Regulatory approvals, granted by bodies such as the FDA or EMA, confirm that a product meets stringent safety, efficacy, and quality standards before entering the market. For instance, in December 2023, Mission Therapeutics Ltd., a UK-based biotechnology company, received FDA approval to initiate a Phase II clinical trial for its lead asset, MTX652, targeting acute kidney injury in high-risk patients following cardiac surgery. MTX652 is designed to target key pathways involved in kidney injury and repair, with the goal of reducing inflammation, preventing further kidney damage, and promoting recovery. A distinctive aspect of this trial is its focus on novel therapeutic mechanisms that address the molecular causes of AKI, potentially offering more effective treatment options compared to current interventions. The Phase II trial will assess MTX652’s safety, efficacy, and pharmacokinetics, generating critical data that could support broader clinical use and eventual regulatory approval.

In July 2022, Terumo Blood and Cell Technologies, a US-based medical equipment manufacturer, partnered with Eliaz Therapeutics Inc. to develop an innovative therapeutic apheresis treatment for acute kidney injury (AKI) and sepsis-induced AKI (S-AKI). This treatment is designed to selectively remove the inflammatory protein Galectin-3 from blood plasma, with the objective of improving patient outcomes, reducing the risk of chronic kidney disease, and lowering hospital mortality rates. Eliaz Therapeutics Inc. is a US-based developer of medical devices specializing in innovative treatments for AKI and S-AKI.

Major players in the acute kidney injury market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Medical Co. Ltd., Teva Pharmaceutical Industries Ltd., Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., Alexion Pharmaceuticals Inc., Alloksys Life Sciences B.V., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB.

North America was the largest region in the acute kidney injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute kidney injury report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute kidney injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute kidney injury (AKI) is characterized by a sudden decline in kidney function, resulting in the buildup of waste products, electrolytes, and fluids within the body. It can develop within hours or days and is commonly triggered by factors such as reduced blood flow, direct kidney damage, or urinary tract obstruction.

The primary types of acute kidney injury include pre-renal, post-renal, and intrinsic kidney injury. Pre-renal kidney injury occurs due to a significant reduction in blood flow to the kidneys, leading to impaired filtration. Treatment options include dialysis, drug therapy, and urinary implants, serving end users such as hospitals, ambulatory surgical centers, and other healthcare facilities.

The acute kidney injury market research report is one of a series of new reports that provides acute kidney injury market statistics, including acute kidney injury industry global market size, regional shares, competitors with an acute kidney injury market share, detailed acute kidney injury market segments, market trends and opportunities, and any further data you may need to thrive in the acute kidney injury industry. This acute kidney injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute kidney injury market includes revenues earned by entities by providing services such as urinalysis & biomarker testing, imaging services, dialysis services, and surgical & interventional procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.